• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
  • Donate
Home / Arthritis News / Ocrelizumab, a Humanized Anti-CD20 Monoclonal Antibody, Studied for the Treatment of RA

Ocrelizumab, a Humanized Anti-CD20 Monoclonal Antibody, Studied for the Treatment of RA

September 29, 2008 By Arthritis Center

Binding of monoclonal antibody to CD20 on the surface of a B cell

Anti-B cell therapy with rituximab has been shown to be safe and beneficial for RA treatment.  Rituximab is approved and marketed for the treatment of RA in patients who have failed other therapies.   Ocrelizumab, a fully human monoclonal antibody against CD20, may have less immunogenicity and less complement activation than rituximab which, theoretically, may reduce the development of drug neutralizing antibodies and infusion reactions.  Here, Genovese at al report the results of a Phase I/II dose finding study of Ocrelizumab in RA patients who have failed other DMARDs (including prior TNF inhibitors).

Methods

The methods and clinical outcomes data for the double-blind portion of this trial were previously reported on this site as part of highlights from the 2006 American College of Rheumatology Annual Scientific Meeting.  Safety data is presented out to 72 weeks.

Results

237 patients (196 ocrelizumab, 41 PLC) were enrolled with mean SJC/TJC, 22/32; RA duration 11 yrs; prior TNF antagonist 47%. 85% of ocrelizumab pts and 76% of PLC pts completed 24 weeks. B cell depletion was observed with all doses of ocrelizumab and was largely sustained over 72 weeks in the higher ocrelizumab dose groups.

Ocrelizumab
ITT population
Week 24 (% pts)
Placebo
(n=41)
10 mg
(n=36)
50 mg
(n=40)
200 mg
(n=40)
500 mg
(n=40)
1000 mg
(n=40)
ACR20 22 42 35 45 50 50
ACR50 7 31 13 25 20 28
ACR70 2 8 3 13 8 18
EULAR mod/good 44 53 40 63 60 65
DAS remission 2 3 5 10 3 8
Week 24 analysis based on Phase I and II subjects

Rates of serious adverse events (SAEs) were similar between groups (17.9% vs. 14.6% for the ocrelizumab vs. placebo groups, respectively).  SAEs reported as related to the drug included supraventricular tachycardia and ophthalmic zoster in patients receiving placebo and an abdominal wall mass, basal cell carcinoma, febrile neutropenia, and lung adenocarcinoma with sepsis in patients receiving ocrelizumab.  Serious infections were reported in 4.9% of placebo and 2.0% of ocrelizumab treated patients and resolved without consequence.  No serious infusion related events were noted in the ocrelizumab treated patients; however, mild to moderate infusion events were seen on the first infusion in approximately half of ocrelizumab treated patients compared to 27% of placebo treated patients.
The incidence of anti-ocrelizumab antibodies was higher in the lower ocrelizumab dosing groups (as high as 19% in the lowest dosing group), but was not clinically related to response

Conclusions

Ocrelizumab was relatively safe and efficacious for the treatment of treatment refractory RA.

Editorial Comment

This study incorporates a large sample size for an early phase trial and is very supportive of a favorable efficacy and safety profile for ocrelizumab.  However, more study is needed to firmly establish efficacy and long-term safety, explore the durability of response, and assess the risk associated with repeat infusions.  Not requiring pre-infusion glucocorticoids is an advantage of this agent; however, the rate of mild to moderate infusion reactions remains substantial based on these data.  A head-to-head trial with rituximab would be the best to establish comparability, even if, at the least, a non-inferiority design was utilized.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Recent News

Exercise Tips for Arthritis Patients

How Does Exercise Affect my Joints? How Frequently Should I Be Exercising? Should I Lose Weight for Exercise to be

Risks and Benefits of Biologic Medications

Victoria Ruffing, RN, BC, Director of Patient Education at the Johns Hopkins Arthritis Center, shares the risks and benefits of biologic for

How to Manage Rheumatoid Arthritis Flares

Through research, doctors have a clearer understanding of how flares can impact a patient on a personal and emotional level. Dr. Uzma Haque

Complementary & Alternative Medicines for Psoriatic Arthritis

There are many complementary & alternative medicines and practices that have been found to be beneficial in curbing arthritis pain,

I can’t be a runner because I have Rheumatoid Arthritis (RA), right?

Dr. Manno discusses running and Rheumatoid Arthritis. Is it an option for the RA patient?

News Categories

  • Ankylosing Spondylitis News
  • Fibromyalgia News
  • Gout News
  • Lupus News
  • Osteoarthritis News
  • Osteoporosis News
  • Psoriatic Arthritis News
  • Rheumatoid Arthritis News
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2023 Johns Hopkins Arthritis Center
Patient Privacy